This nanoparticle‐based lithium delivery method offers a promising therapeutic approach for brain disorders dependent on GSK‐3β activation, including mood disorders, tauopathies, and Alzheimer's disease. The gene discussed is GSK3B; the disease is early-onset autosomal dominant Alzheimer disease.